Cited by 116Hepatitis B Virus StudiesHepatitis Viruses Studies and EpidemiologyTravel-related health issues

The DOI matches its Crossref record; 33 of the 38 references it cites were found in a registry or an index.

Immunogenicity of combined hepatitis A and B vaccine in elderly persons

Wolters, Bernd, Junge, Ulrich, Dziuba, Stefan, Roggendorf, Michael·2003·Vaccine

Open this paper in CoChat — free account

Abstract

More and more elderly people travel to areas where hepatitis A and B are endemic. Their immune system is less effective than in young persons. Therefore, it has to be insured that these travelers have protective immunity after vaccination. In a retrospective study we measured anti hepatitis virus (anti-HAV) and anti-HBs in elderly persons (N = 104, mean age 54 years) after combined hepatitis A/B vaccination under every-day conditions. After complete vaccination only 36 (34.6%) had antibodies against both viruses. Only 23 (29%) of 80 vaccinees older than 40 years were protected against hepatitis B and 52 (65%) against hepatitis A. The response to the vaccination decreased with increasing age. Vaccination against hepatitis B-but not against hepatitis A-was also influenced by the presence of chronic disease. After one booster 87% of the anti-HAV negative vaccinees developed protective anti-HAV antibodies. Anti-HBs can be expected in about 50% of the HBV negative vaccinees with every single booster. These results indicate that combined hepatitis A/B vaccination is not very effective in elderly persons. After complete vaccination their anti-HAV and anti-HBs antibodies have to be controlled to insure protection. In case of vaccination-failure boosters are very effective.

Integrity signals

Registry

Crossref · 10.1016/s0264-410x(03)00399-2

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Risk Factors for Lack of Detectable Antibody Following Hepatitis B Vaccination of Minnesota Health Care Workers
Wood, R. C. (1993) · JAMA · doi:10.1001/jama.1993.03510240047030 · Cited by 286
Incidence and Risk Factors for Acute Hepatitis B in the United States, 1982–1998: Implications for Vaccination Programs
Goldstein, S. T., Alter, M. J., Williams, I. T., Moyer, L. A., Judson, F. N., Mottram, K., Fleenor, M. E., Ryder, P. L., & Margolis, H. S. (2002) · The Journal of Infectious Diseases · doi:10.1086/339192 · Cited by 281
Federal Statistical Office, Germany
(2003) · Choice Reviews Online · doi:10.5860/choice.41-1312 · Cited by 196
The first combined vaccine against hepatitis A and B: an overview
Thoelen, S., Damme, P. V., Leentvaar-Kuypers, A., Leroux-Roels, G. G., Bruguera, M., Frei, P. C., Bakasénas, V., & Safary, A. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00421-6 · Cited by 121
A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix®) with corresponding monovalent vaccines (Havrix® and Engerix-B®) in adults
Joines, R. W., Blatter, M. M., Abraham, B., Xie, F., Clercq, N. D., Baine, Y., Reisinger, K. S., Kuhnen, A. E., & Parenti, D. L. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00240-7 · Cited by 110
Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience
Rendi‐Wagner, P., Kundi, M., Stemberger, H., Wiedermann, G., Holzmann, H., Hofer, M., Wiesinger, K., & Kollaritsch, H. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00410-2 · Cited by 109
Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen
McMahon, B. J., Parkinson, A. J., Helminiak, C., Wainwright, R. B., BULKOW, L. R., Kellerman-Douglas, A., Schoenberg, S., & Ritter, D. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90851-o · Cited by 97
Hepatitis-B Vaccination in the Elderly
Denis, F., Mounier, M., Hessel, L., Michel, J., Gualde, N., Dubois, F., Barin, F., & Goudeau, A. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/149.6.1019 · Cited by 95
Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998
Thierfelder, W., Hellenbrand, W., Meisel, H., Schreier, E., & Dortschy, R. (2001) · European Journal of Epidemiology · doi:10.1023/a:1013792013184 · Cited by 83
The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults
Reuman, P. D., Kubilis, P. S., Hurni, W. M., Brown, L., & Nalin, D. R. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00310-6 · Cited by 78

Show all 38 references

Research works printed but not linked: 3

FDA approval for a combined hepatitis A and B vaccine. MMWR Morb Mortal Wkly Rep 2001;50:806–7.
Keystone J, Parsons J, Anstey R. Reactogenicity and immunogenicity of a combined vaccine against hepatitis A and B in older adults. In: Proceedings of the Ninth Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, 21–25 April 1996, C324.
Hofmann, 1997, Zur Effizienz der Hepatitis B-Schutzimpfung, Gesundheitswesen, 59, 527

Sorted by citations

Factors That Influence the Immune Response to Vaccination
Zimmermann, P., & Curtis, N. C. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00084-18 · Cited by 970
The Xs and Y of immune responses to viral vaccines
Klein, S. L., Jedlicka, A., & Pekosz, A. S. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70049-9 · Cited by 813
How sex and age affect immune responses, susceptibility to infections, and response to vaccination
Giefing, C., Berger, P., Lepperdinger, G., & Grubeck‐Loebenstein, B. (2015) · Aging Cell · doi:10.1111/acel.12326 · Cited by 796
Biology of Immune Responses to Vaccines in Elderly Persons
Weinberger, B., Herndler‐Brandstetter, D., Schwanninger, A., Weiskopf, D., & Grubeck‐Loebenstein, B. (2008) · Clinical Infectious Diseases · doi:10.1086/529197 · Cited by 392
SARS-CoV-2, COVID-19 and the aging immune system
Bartleson, J. M., Radenkovic, D., Covarrubias, A. J., Furman, D., Winer, D. A., & Verdin, E. (2021) · Nature Aging · doi:10.1038/s43587-021-00114-7 · Cited by 359
Medical Virology of Hepatitis B: how it began and where we are now
Gerlich, W. H. (2013) · Virology Journal · doi:10.1186/1743-422x-10-239 · Cited by 349
Sexual dimorphism of humoral immunity with human vaccines
Cook, I. F. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.054 · Cited by 320
Immunogenicity of a two-dose investigational hepatitis b vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults
Jackson, S., Lentino, J., Kopp, J., Murray, L., Ellison, W., Rhee, M., Shockey, G., Akella, L., Erby, K., Heyward, W. L., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.038 · Cited by 197
Factors influencing immunologic response to hepatitis B vaccine in adults
Yang, S., Tian, G., Cui, Y., Ding, C., Deng, M., Yu, C., Xu, K., Ren, J., Yao, J., Li, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep27251 · Cited by 193
Development of the CpG Adjuvant 1018: A Case Study
Campbell, J. D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6445-1_2 · Cited by 190
Vaccines for the elderly: current use and future challenges
Weinberger, B. (2018) · Immunity & Ageing · doi:10.1186/s12979-017-0107-2 · Cited by 168
The ageing B cell population: Composition and function
Ademokun, A., Wu, Y.-C. B., & Dunn‐Walters, D. K. (2009) · Biogerontology · doi:10.1007/s10522-009-9256-9 · Cited by 146
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age
Heyward, W. L., Kyle, M., Blumenau, J., Davis, M., Reisinger, K. S., Kabongo, M. L., Bennett, S. R., Janssen, R. S., Namini, H., & Martin, J. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.068 · Cited by 121
Prevention of Hepatitis A with the Hepatitis A Vaccine
Craig, A. S., & Schaffner, W. (2004) · New England Journal of Medicine · doi:10.1056/nejmcp031540 · Cited by 115
Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
Ho, J. K., Jeevan-Raj, B. P., & Netter, H. J. (2020) · Viruses · doi:10.3390/v12020126 · Cited by 105
Vaccines for the elderly
Weinberger, B., & Grubeck-Loebenstein, B. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03944.x · Cited by 104
B cell repertoire and ageing
Dunn‐Walters, D. K., & Ademokun, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.009 · Cited by 103
Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives
Gerlich, W. H. (2014) · Medical Microbiology and Immunology · doi:10.1007/s00430-014-0373-y · Cited by 99
Excellent Response Rate to a Double Dose of the Combined Hepatitis A and B Vaccine in Previous Nonresponders to Hepatitis B Vaccine
Cardell, K., Åkerlind, B., Sällberg, M., & Frydén, A. (2008) · The Journal of Infectious Diseases · doi:10.1086/589722 · Cited by 96
Hepatitis A/B vaccination of adults over 40 years old: Comparison of three vaccine regimens and effect of influencing factors
der Wielen, M. V., Damme, P. V., Chlíbek, R., Smetana, J., & von Sonnenburg, F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.04.016 · Cited by 92
CD25-Expressing CD8+ T Cells Are Potent Memory Cells in Old Age
Herndler‐Brandstetter, D., Schwaiger, S., Veel, E., Fehrer, C., Cioca, D., Almanzar, G., Keller, M., Pfister, G., Parson, W., Würzner, R., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1566 · Cited by 86
A systems biology approach to the effect of aging, immunosenescence and vaccine response
Poland, G. A., Ovsyannikova, I. G., Kennedy, R. B., Lambert, N. D., & Kirkland, J. L. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.04.005 · Cited by 85
Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50–90 years
Weinberger, B., Keller, M., Fischer, K.-H., Stiasny, K., Neuner, C., Heinz, F. X., & Grubeck‐Loebenstein, B. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.024 · Cited by 85
Immune Response of Hepatitis B Vaccine Among Persons With Diabetes
Schillie, S. F., Spradling, P. R., & Murphy, T. V. (2012) · Diabetes Care · doi:10.2337/dc12-0312 · Cited by 83
Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal®) in the Elderly
D’Acremont, V., Herzog, C., & Genton, B. (2006) · Journal of Travel Medicine · doi:10.1111/j.1708-8305.2006.00001.x · Cited by 74
Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double-Blind, Placebo-Controlled, Phase 1-2 Clinical Trial (ABDALA Study)
Hernández‐Bernal, F., Ricardo-Cobas, M. C., Martín‐Bauta, Y., Rodríguez, Z. N., Piñera-Martínez, M., Quintana-Guerra, J., Urrutia-Pérez, K., Urrutia-Pérez, K., Chávez-Chong, C. O., Hernández, J. L. A., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101383 · Cited by 69
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine
Sablan, B. P., Kim, D. J., Barzaga, N. G., Chow, W. C., Cho, M., Ahn, S. H., Hwang, S. G., Lee, J.-H., Namini, H., & Heyward, W. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.001 · Cited by 68
Vaccines in Travel Health: From Risk Assessment to Priorities
Steffen, R. J., & Connor, B. A. (2006) · Journal of Travel Medicine · doi:10.2310/7060.2005.00006 · Cited by 65
Immunosenescence and inflamm-ageing in COVID-19
Zinatizadeh, M. R., Zarandi, P. K., Ghiasi, M., Kooshki, H., Mohammadi, M., Amani, J., & Rezaei, N. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101818 · Cited by 69
Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities
Tohme, R. A., Awosika‐Olumo, D., Nielsen, C., Khuwaja, S. A., Scott, J., Xing, J., Drobeniuc, J., Hu, D. J., Turner, C., Wafeeg, T., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.10.011 · Cited by 57
Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60–70 years
Hyer, R. N., & Janssen, R. S. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.08.005 · Cited by 55
Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?
Hazeldine, J., & Lord, J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573662 · Cited by 55
Hepatitis A vaccines and the elderly
Genton, B., D’Acremont, V., Furrer, H.-J., Hatz, C., & Loutan, L. (2005) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2005.10.002 · Cited by 50
Mechanistic insights into the impairment of memory B cells and antibody production in the elderly
Aberle, J. H., Stiasny, K., Kundi, M., & Heinz, F. X. (2012) · AGE · doi:10.1007/s11357-011-9371-9 · Cited by 50
Can the Immune System Still Be Efficient in the Elderly? An Immunological and Immunoendocrine Therapeutic Perspective
Pfister, G., & Savino, W. (2008) · NeuroImmunoModulation · doi:10.1159/000156477 · Cited by 44
A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine
Damme, P. V., & Herck, K. V. (2004) · Expert Review of Vaccines · doi:10.1586/14760584.3.3.249 · Cited by 43
Prevention of hepatitis A by Havrix™: a review
Herck, K. V., & Damme, P. V. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.4.459 · Cited by 42
Hepatitis vaccination among drug users
Quaglio, G., Lugoboni, F., Mezzelani, P., Jarlais, D. C. D., & Lechi, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.12.045 · Cited by 42
Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age
Janssen, J. M., Jackson, S., Heyward, W. L., & Janssen, R. S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.070 · Cited by 42
Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond
Weinberger, B. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00249-6 · Cited by 44
Immunizations in Older Adults
High, K. P. (2007) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2007.03.007 · Cited by 40
Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults
Weinberger, B., Haks, M. C., de Paus, R. A., Ottenhoff, T. H. M., Bauer, T., & Grubeck‐Loebenstein, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01035 · Cited by 39
Immunoprevention and immunotherapy of cancer in ageing
Provinciali, M., & Smorlesi, A. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0539-3 · Cited by 39
Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis
Meeren, O. V. D., Crasta, P. D., Cheuvart, B., & Ridder, M. D. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1039758 · Cited by 39
Hepatitis B vaccination of susceptible elderly residents of long term care facilities during a hepatitis B outbreak
Williams, R., Seña, A. C., Moorman, A. C., Moore, Z., Sharapov, U. M., Drobenuic, J., Hu, D. J., Wood, H., Xing, J., & Spradling, P. R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.078 · Cited by 36
Implications of inflammatory states on dysfunctional immune responses in aging and obesity
Thomas, A. L., Alarcon, P. C., Divanovic, S., Chougnet, C. A., Hildeman, D. A., & Moreno-Fernandez, M. E. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.732414 · Cited by 35
Systems Biology of Vaccination in the Elderly
Duraisingham, S., Rouphael, N., Cavanagh, M., Nakaya, H. I., Goronzy, J. J., & Pulendran, B. (2012) · Current topics in microbiology and immunology · doi:10.1007/82_2012_250 · Cited by 34
The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E
Dong, C., Dai, X., & Meng, J.-H. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.11.001 · Cited by 32
Revaccination with Fendrix® or HBVaxPro® results in better response rates than does revaccination with three doses of Engerix-B® in previous non-responders
Hoebe, C. J. P. A., Vermeiren, A. P. A., & Dukers–Muijrers, N. H. T. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.074 · Cited by 32
Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review
Bakker, M., Bunge, E. M., Marano, C., Ridder, M. D., & Moerlooze, L. D. (2016) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1150182 · Cited by 32
Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study
Cramer, J. P., Dubischar, K. L., Eder, S., Burchard, G. D., Jelı́nek, T., Jilma, B., Kollaritsch, H., Reisinger, E. C., & Westritschnig, K. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.07.029 · Cited by 28
Comparative Analysis of B-Cell Receptor Repertoires Induced by Live Yellow Fever Vaccine in Young and Middle-Age Donors
Davydov, A. N., Obraztsova, A., Lebedin, M. Y., Turchaninova, M. A., Staroverov, D. B., Merzlyak, E. M., Sharonov, G. V., Кладова, О. В., Shugay, M., Britanova, O. V., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02309 · Cited by 29
Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults
Höhler, T., Groeger-Bicanic, G., Hoet, B., & Stoffel, M. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.024 · Cited by 28
The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route
Edelman, R., Deming, M. E., Toapanta, F. R., Heuser, M. D., Chrisley, L., Barnes, R. S., Wasserman, S. S., Blackwelder, W. C., Handwerger, B. S., Pasetti, M. F., et al. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00179-9 · Cited by 24
The use of dried blood spots for assessing antibody response to hepatitis A virus after natural infection and vaccination
Melgaço, J. G., Pinto, M. A., Rocha, A. M., Freire, M. D. S., Gaspar, L. P., de Lima, S. M. B., Cruz, O. G., & Vitral, C. L. (2010) · Journal of Medical Virology · doi:10.1002/jmv.21973 · Cited by 24
Enhanced Mucosal Immune Responses Induced by a Combined Candidate Mucosal Vaccine Based on Hepatitis A Virus and Hepatitis E Virus Structural Proteins Linked to Tuftsin
Gao, Y., Su, Q., Yao, Y., Jia, Z., Wang, H., Lu, X., Qiu, F., & Bi, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123400 · Cited by 22
Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine
Beran, J. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.6.891 · Cited by 22
A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases
Kaslow, D. C. (2004) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2004.03.007 · Cited by 22
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥ 50 years
Gilbert, C. L., Klopfer, S. O., Martin, J. C., Schödel, F. P., & Bhuyan, P. K. (2011) · Human Vaccines · doi:10.4161/hv.7.12.18333 · Cited by 21
Immunizations in the elderly: do they live up to their promise?
Herndler‐Brandstetter, D., Cioca, D., & Grubeck‐Loebenstein, B. (2006) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-006-0267-8 · Cited by 20
Characterization of MHC-II antigen presentation by B cells and monocytes from older individuals
Clark, H. L., Banks, R. E., Jones, L., Hornick, T. R., Higgins, P. A., Burant, C., & Canaday, D. H. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.06.005 · Cited by 18
The international epidemiological transition and the education gender gap
Klasing, M. J., & Milionis, P. (2020) · Journal of Economic Growth · doi:10.1007/s10887-020-09175-6 · Cited by 18
Anti-hepatitis B core antibody is not required for prevaccination screening in healthcare workers
Shim, J., Kim, K. Y., Kim, B., Chun, H., Lee, M. S., Hwangbo, Y., Jang, J. Y., Dong, S. H., Kim, H. J., Chang, Y. W., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.11.044 · Cited by 15
Relationship between Systemic Inflammation and Delayed-Type Hypersensitivity Response to Candida Antigen in Older Adults
Pence, B. D., Lowder, T., Keylock, K. T., Vieira‐Potter, V. J., Cook, M. D., McAuley, E., & Woods, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036403 · Cited by 13
How to Effectively Monitor Aging Patients with Chronic Hepatitis B: A Review
Kang, C. K., Brennan, P., & Dillon, J. F. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s366255 · Cited by 12
Vaccinations in Older Adults with Gastrointestinal Diseases
Horton, H. A., Kim, H., & MELMED, G. Y. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.10.002 · Cited by 12
Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial
Wolters, B., Müller, T., Ross, R. S., Clauberg, R., Werfel, U., Roggendorf, H., Siggelkow, C., Hausen, T., & Roggendorf, M. (2009) · Human Vaccines · doi:10.4161/hv.5.4.7051 · Cited by 12
Self-citation
Letter to the Editor
Nothdurft, H. D., Aumüller, H., Aumüller, R., Dames, W., Stamer, K., Kroetzsch, H., & Kulow, M. (2003) · Vaccine · doi:10.1016/j.vaccine.2003.08.049 · Cited by 12
Hepatitis als Reisekrankheit
Hadem, J., Wedemeyer, H. H., & Manns, M. P. (2004) · Der Internist · doi:10.1007/s00108-004-1197-4 · Cited by 11
Fatal Outcome of Hepatitis A Virus (HAV) Infection in a Traveler with Incomplete HAV Vaccination and Evidence of Rift Valley Fever Virus Infection
Oltmann, A., Kämper, S., Staeck, O., Schmidt‐Chanasit, J., Günther, S., Berg, T., Frank, C., Krüger, D. H., & Hofmann, J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01102-08 · Cited by 10
High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease
Study, T. S. H. C., Schüpbach, J., Bisset, L. R., Regenass, S., Bürgisser, P., Gorgievski, M., Steffen, I., Andreutti, C., Martinetti, G., Shah, C., et al. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-254 · Cited by 10
A Double‐Dose Hepatitis B Vaccination Schedule in Travelers Presenting for Late Consultation
Wong, J., Payne, M., & Hollenberg, S. (2014) · Journal of Travel Medicine · doi:10.1111/jtm.12123 · Cited by 9
Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
Yeo, S. J., Lee, H. S., Jang, B. I., Kim, E. S., Jeon, S. W., Kim, K. O., Kim, K. O., Lee, H. J., Lee, H. J., Park, K. S., et al. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.3.400 · Cited by 9
Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine
Campbell, J. D., Chambers, C. V., Brady, R. C., Caldwell, M. C., Bennett, N. L., Fourneau, M., Jain, V. K., & Innis, B. L. (2011) · Human Vaccines · doi:10.4161/hv.7.1.13553 · Cited by 9
A Case of In-flight Transmission of Severe Acute Respiratory Syndrome (SARS): SARS Serology Positive
Wilder‐Smith, A., & Leong, H. N. (2006) · Journal of Travel Medicine · doi:10.2310/7060.2004.17091 · Cited by 9
Hepatitis B vaccine immunogenicity among adults vaccinated during an outbreak response in an assisted living facility—Virginia, 2010
Bender, T. J., Sharapov, U. M., Utah, O. F., Xing, J., Hu, D. J., Rybczyńska, J., Drobeniuc, J., Kamili, S., Spradling, P. R., & Moorman, A. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.12.018 · Cited by 8
Analysis of the effect of cytomegalovirus infection in clinical outcomes and prolonged duration of SARS-CoV-2 shedding in intensive care unit patients with COVID-19 pneumonia
Shen, H., Feng, J., Sun, C.-Y., Huang, J.-R., Chen, Y., Chen, W., & Yang, K. (2023) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231209150 · Cited by 7
Primary Hepatitis A vaccination failure is a rare although possible event: results of a retrospective study
Bonanni, P., Bechini, A., Pesavento, G., Guadagno, R., Santini, M. G., Baretti, S., Bartoloni, A., & Taliani, G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.020 · Cited by 7
Vaccine responses in ageing and chronic viral infection
Rees-Spear, C., & McCoy, L. E. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab007 · Cited by 8
Combined hepatitis A and B vaccine in elderly
Damme, P. V., Herck, K. V., & der Wielen, M. V. (2003) · Vaccine · doi:10.1016/j.vaccine.2003.08.011 · Cited by 7
Lifelong Maintenance of Oral Tolerance and Immunity Profiles in Mice Depends on Early Exposure to Antigen
Speziali, E., Menezes, J. S., Santiago, A. F., Vaz, N. M., & Faria, A. M. C. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12635 · Cited by 6
Hepatitis A+B Vaccine in Elderly Persons
Wiedermann, G. (2006) · Journal of Travel Medicine · doi:10.1111/j.1708-8305.2004.tb00139.x · Cited by 6
Simultaneous vaccination against hepatitis A and B: results of an open, randomized study from the occupational health point of view.
Rieger, M. A., Hofmann, F., & Michaelis, M. (2004) · PubMed · Cited by 6
Acute and Chronic Viral Hepatitis
Hochman, J. A., & Balistreri, W. F. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547409.019 · Cited by 5
Studies on Hepatitis B Vaccination and Factors Associated with the Vaccine Response
Cardell, K. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 5
Hepatitis A breakthrough infections despite vaccination: A systematic review and meta-analysis
Schnyder, J. L., Hutten, D., Bache, E. B., Spijker, R., Welkers, M. R. A., de Jong, H. K., Grobusch, M. P., & Goorhuis, A. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108113 · Cited by 4
Persistence of immunity in healthy adults aged ≥50 years primed with a hepatitis B vaccine 3 years previously
Sharma, R., Ahlm, C., Østergaard, L. J., Dowell, A., Tran, C., Thomas, S., & Eymin, C. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1019187 · Cited by 4
Global, regional, and national burden of liver cancer due to hepatitis B, 1990–2021 and projections to 2051: a systematic analysis of the Global Burden of Disease Study 2021
Yang, P., Huang, W., Xu, Y., Li, Q., Shu, X., Zuo, J., Ren, W., Huang, Y., Teng, Y., & Shu, P. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003053 · Cited by 3
IMMUNOSENESCENCE - INEVITABLE OR PREVENTABLE?
Kalula, S., & Ross, K. A. (2008) · Cited by 3
Prävention der Virushepatitis A bis E
Cornberg, M., & Manns, M. P. (2011) · Der Internist · doi:10.1007/s00108-010-2678-2 · Cited by 3
Viral Hepatitis A in Children: Detection and Management
Sintusek, P., Sa‐nguanmoo, P., & Poovorawan, Y. (2019) · Springer eBooks · doi:10.1007/978-981-13-0050-9_5 · Cited by 2
Vaccination in Patients with Chronic Lymphocytic Leukemia: Current Problems
Kislova, M. I., Petrenko, A. A., Костинов, М. П., & Nikitin, E. A. (2021) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2021-20-3-91-106 · Cited by 2
Strategy for hepatitis A seroprevalence survey in a population of young people
Mongillo, M., Chiara, F., Ranzato, M., & Trevisan, A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.044 · Cited by 2
Novel Strategies for Improved Vaccines for the Elderly: The Example of Influenza
Giudice, G. D., & Rappuoli, R. (2011) · Springer eBooks · doi:10.1007/978-3-0346-0219-8_10 · Cited by 2
Vaccination for Older Adults in India: Position Statement of the Indian Academy of Geriatrics
Singhal, S., Dewangan, G. C., Mehta, P. K., Viggeswarpu, S., Dey, A. B., & Gunasekaran, V. (2026) · Journal of The Indian Academy of Geriatrics · doi:10.4103/jiag.jiag_42_26 · Cited by 1
Vaccination contre l’hépatite A
Buisson, Y., & Nicand, É. (2005) · EMC - Hépato-Gastroenterologie · doi:10.1016/j.emchg.2004.12.007 · Cited by 1
Vaccination in the Elderly
Weinberger, B., & Grubeck‐Loebenstein, B. (2011) · Springer eBooks · doi:10.1007/978-3-0346-0219-8_8 · Cited by 2
Factors associated with the non-development of immunogenicity in vaccinated adults against the hepatitis B virus
de Tai, S. M.-T., Arana-Calderón, C. A., & Aguirre-Quispe, W. (2021) · Vacunas (English Edition) · doi:10.1016/j.vacune.2021.10.004 · Cited by 1
The Efficacy of Vaccines to Prevent Infectious Diseases in the Elderly
Herndler‐Brandstetter, D., & Grubeck‐Loebenstein, B. (2007) · Springer eBooks · doi:10.1007/978-0-387-76842-7_10 · Cited by 1
Hepatitis B Virus Vaccine Response in Children 15–19 Years Old
Ivanova, L. V., & Rusev, V. (2005) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2005.10817267 · Cited by 1

Authors: Wolters, B., Junge, U., Dziuba, S., & Roggendorf, M.
Affiliations: University of Duisburg-Essen (DE)
Klinikum Bielefeld (DE)
Corresponding author: Roggendorf, Michael
ORCID: Roggendorf, Michael
Venue: Vaccine
Publisher: Elsevier BV
Published: 2003-09
Volume: 21
Issue: 25-26
Pages: 3623-3628
ISSN: 0264-410X (ISSN-L)
DOI: 10.1016/s0264-410x(03)00399-2
OpenAlex: W1980161689
Cited by: 116
References: 38
Citations by year: 2026: 2 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 10 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 4 · 2015: 5 · 2014: 3 · 2013: 5 · 2012: 10
FWCI: 6.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Vaccine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Health Sciences › Medicine › Hepatology › Hepatitis Viruses Studies and Epidemiology
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
Keywords: immunogenicity, older adults, anti-HAV antibodies, anti-HBs antibodies, vaccine response, booster vaccination, vaccine failure, chronic disease, travel vaccination, age-related immune decline
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Female, Health Status, Hepatitis B Surface Antigens, Humans, Immunization Schedule, Immunization, Secondary, Male, Middle Aged, Retrospective Studies, Hepatitis B Vaccines, Vaccines, Combined, Hepatitis A Vaccines, Hepatitis A Antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunogenicity of combined hepatitis A and B vaccine in elderly persons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks